Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CDC25A | P30304 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CETP | P11597 | 3/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14000864 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL21580898 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL19458808 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL27699112 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL20482670 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL20483366 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL27542770 | 1.00 | LMNA (0.58) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL28786169 | 0.98 | LMNA (0.56) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL29267508 | 0.91 | LPAR3 (0.53) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL27747029 | 0.91 | LPAR3 (0.53) | LMNAESR1ADORA3CDC25AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109517008-A | The preparation method of n-hexadecyl phosphocholine and its application as vaccine immunity adjuvant | 暨南大学 | 2019-03-26 | — | — | CN | claimed |
| CN-103228266-B | Ternary mixture formulation | 健康科学西部大学 | 2017-11-14 | — | — | CN | claimed |
| CN-103338747-A | Carrier for localized release of hydrophilic prodrugs | KONINKL PHILIPS ELECTRONICS NV | 2013-10-02 | — | — | CN | claimed |
| CN-103228266-A | Ternary mixture formulation | UNIV WESTERN HEALTH SCIENCES | 2013-07-31 | — | — | CN | claimed |
| CN-102596203-A | Liquid pharmaceutical forms of alkylphosphocholines and processes for their preparation | EXPERGEN DRUG DEV GMBH | 2012-07-18 | — | — | CN | claimed |
| CN-102573800-A | Ophthalmic drug delivery system comprising phospholipids and cholesterol | TAIWAN LIPOSOME CO LTD | 2012-07-11 | — | — | CN | claimed |
| CN-101340918-A | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| CN-1622811-A | Use of alkylphosphocholines for the preventative treatment of protozoan diseases | ZENTARIS AG (DE) | 2005-06-01 | — | — | CN | claimed |
| CN-1283111-A | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis | ASTA MIDICA AG (DE) | 2001-02-07 | — | — | CN | claimed |
| CN-1202829-A | Method for preserving microoganisms | CORTECS LTD (GB) | 1998-12-23 | — | — | CN | claimed |
| CN-111432846-A | Semiconductor SWCNT dispersion for bioimaging and method for producing same | 株式会社岛津制作所 | 2020-07-17 | — | — | CN | disclosed |
| CN-111356481-A | Semiconductor SWCNT dispersion for bioimaging and method for examining the same | 株式会社岛津制作所 | 2020-06-30 | — | — | CN | disclosed |
| CN-110526912-A | Heteroaryl compound for kinase inhibition | ARIAD PHARMA INC | 2019-12-03 | — | — | CN | disclosed |
| CN-106559991-B | heteroaryl compounds for kinase inhibition | 阿里亚德医药股份有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-110256484-A | A kind of preparation method of Miltefosine | 成都百事兴科技实业有限公司 | 2019-09-20 | — | — | CN | disclosed |
| CN-1283111-A | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis | ASTA MIDICA AG (DE) | 2001-02-07 | — | — | CN | disclosed |
| CN-1247470-A | Methods of using cyclooxygenase-2 inhibitors as anti-angiogenic agents | SEARLE & CO (US) | 2000-03-15 | — | — | CN | disclosed |
| CN-1202829-A | Method for preserving microoganisms | CORTECS LTD (GB) | 1998-12-23 | — | — | CN | disclosed |
| CN-1163575-A | Immunogenic compositions | CORTECS CO LTD (GB) | 1997-10-29 | — | — | CN | disclosed |
| CN-1092321-A | Avoid the method for multi-drug resistance in the cancerous cell | UNIV ILLINOIS (US) | 1994-09-21 | — | — | CN | disclosed |